Research programme: antipsychotic therapeutics - Spectrum

Drug Profile

Research programme: antipsychotic therapeutics - Spectrum

Alternative Names: NEO 376; NEO 392; SPI 376; SPI 392

Latest Information Update: 02 Jul 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spectrum Pharmaceuticals
  • Class
  • Mechanism of Action Dopamine D4 receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psychotic disorders

Most Recent Events

  • 02 Jul 2003 Spectrum Pharmaceuticals are seeking licensing partners for these agents (
  • 02 Jul 2003 Discontinued - Preclinical for Psychotic disorders in USA (unspecified route)
  • 19 Dec 2002 Preclinical trials in Psychotic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top